ArticleNature communications2026
Infection-acquired protection against SARS-CoV-2 infection and clinical severity by number of prior infections.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
SARS-CoV-2 reinfections have increased since Omicron and are common. Yet, as we approach endemicity, the frequency, severity, and consequences of reinfections remain poorly understood. Using data from a household transmission study in Managua, Nicaragua (2020-2024), we evaluated protection conferred by one, two, and three+ prior infections and compared the severity of first, second, and third+ RT-PCR-confirmed SARS-CoV-2 infections. Compared to those with no prior infections, one, two, and three+ prior infections were associated with increasing protection from symptomatic infection, with incidence rate ratios of 0.39, (95% Confidence Interval [CI]: 0.26-0.61), 0.24 (95%CI: 0.13-0.42), and 0.20 (95%CI: 0.09-0.42), respectively. Among RT-PCR-confirmed infections, reinfections were associated with decreased severity; compared with first infections, second infections had 1.57 (95%CI: 1.15-2.16) times the proportion of subclinical disease and 0.65 (95%CI: 0.49-0.86) times the proportion of moderate/severe disease. Our findings suggest that protection generated from two prior infections may be stronger than one prior infection, although additional benefit beyond the second infection was not clearly observed. Together, our results suggest we are approaching an endemic phase of SARS-CoV-2 characterized by reduced severity relative to first infections, yet the burden remains high, underscoring the importance of maintaining immunity to manage ongoing disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.